Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for NovoCure Limited (NVCR : NSDQ)

• Company Description    NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands. Number of Employees: 1,605

• Price / Volume Information    Yesterday's Closing Price: $17.96 Daily Weekly Monthly 20 Day Moving Average: 1,975,312 shares Shares Outstanding: 115.82 (millions) Market Capitalization: $2,080.15 (millions) Beta: 0.90 52 Week High: $20.06 52 Week Low: $9.82 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 42.65% 35.68% 12 Week 30.62% 20.75% Year To Date 38.90% 27.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL NO. 4 THE FORUM GRENVILLE STREET - ST. HELIER,Y9 JE2 4UF JEY ph: 44-0-15-3475-6700 fax: - investorinfo@novocure.com http://www.novocure.com

• General Corporate Information    Officers Frank Leonard - Chief Executive Officer William F. Doyle - Executive Chairman and Director Christoph Brackmann - Chief Financial Officer Asaf Danziger - Director Jeryl L. Hilleman - Director Peer Information NovoCure Limited (CORR.) NovoCure Limited (RSPI) NovoCure Limited (CGXP) NovoCure Limited (BGEN) NovoCure Limited (GTBP) NovoCure Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G6674U108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 07/23/26 Share - Related Items Shares Outstanding: 115.82 Most Recent Split Date: (:1) Beta: 0.90 Market Capitalization: $2,080.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.55 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.29 Price/Cash Flow: - Price / Sales: 3.08 EPS Growth vs. Year Ago Period: -100.00% vs. Previous Quarter: -181.82% Sales Growth vs. Year Ago Period: 12.30% vs. Previous Quarter: -0.17% ROE 03/31/26 - -50.82 12/31/25 - -39.11 09/30/25 - -50.29 ROA 03/31/26 - -16.48 12/31/25 - -11.69 09/30/25 - -13.94 Current Ratio 03/31/26 - 2.90 12/31/25 - 2.90 09/30/25 - 1.55 Quick Ratio 03/31/26 - 2.70 12/31/25 - 2.71 09/30/25 - 1.50 Operating Margin 03/31/26 - -25.66 12/31/25 - -20.79 09/30/25 - -27.66 Net Margin 03/31/26 - -25.66 12/31/25 - -20.79 09/30/25 - -27.66 Pre-Tax Margin 03/31/26 - -25.98 12/31/25 - -20.79 09/30/25 - -23.43 Book Value 03/31/26 - 2.86 12/31/25 - 3.04 09/30/25 - 3.05 Inventory Turnover 03/31/26 - 4.08 12/31/25 - 4.17 09/30/25 - 4.11 Debt-to-Equity 03/31/26 - 0.71 12/31/25 - 0.70 09/30/25 - 0.57 Debt-to-Capital 03/31/26 - 41.53 12/31/25 - 41.01 09/30/25 - 36.31

Powered by Zacks Investment Research ©